Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial

Zhanjie Zhang; Bian Wu; Gang Peng; Guixiang Xiao; Jing Huang; Qian Ding; Chengzhang Yang; Xingao Xiong; Hui Ma; Liangliang Shi; Jinsong Yang; Xiaohua Hong; Jielin Wei; You Qin; Chao Wan; Yi Zhong; Yan Zhou; Xueyan Zhao; Yangming Leng; Tao� Zhang; Gang Wu; Min Yao; Xiaomeng Zhang; Kunyu Yang

doi:10.1158/1078-0432.ccr-22-0666

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Neoadjuvant chemotherapy plus camrelizumab for locally advanced HNSCC showed high ORR, pCR, and MPR rates, with an acceptable safety profile. These data support further evaluation of neoadjuvant chemoimmunotherapy for the treatment of locally advanced HNSCC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhang et al. (2022) studied this question.

synapsesocial.com/papers/69d80b4145af6083e6ae2aef https://doi.org/10.1158/1078-0432.ccr-22-0666

View Full Paper

Ask AI

Bookmark

Share

Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial

Ask about this paper

Abstract

Discussion

Cite This Study

Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading